The effect of omega-3 supplements on the serum levels of ACE/ACE2 ratio as a potential key in cardiovascular disease: A randomized clinical trial in participants with vitamin D deficiency
- PMID: 37090459
- PMCID: PMC10117361
- DOI: 10.18549/PharmPract.2023.1.2761
The effect of omega-3 supplements on the serum levels of ACE/ACE2 ratio as a potential key in cardiovascular disease: A randomized clinical trial in participants with vitamin D deficiency
Abstract
Objective: The aim of this randomized controlled clinical trial was to determine the effect of the omega-3 fatty acid supplementations 300 mg per day for 8 weeks on the serum levels of ACE/ACE2 ratio in Jordanian participants with vitamin D deficiency (VDD).
Methods: The physical and clinical characteristic of individuals in both intervention and control randomized controlled clinical trial were measured and analyzed. The comparisons between the two groups and the changes in each group before and after taking omega-3 doses were studied through independent t test and paired t test, respectively. Possible factors that have a role in the changes were determined by multivariate stepwise regression. Follow-up period lasted 10 weeks.
Results: The sample consisted of 82 participants with VDD and a mean age of 37.85 ± 9.85 years. Omega-3 Supplements resulted in a significant decrease in serum ACE levels, ACE/ACE2 ratio and serum 25-hydroxy vitamin D (25OHD). While the change in serum ACE2 levels and serum triglycerides levels were insignificant. Also, a significant increase in serum LDL levels were observed.
Conclusion: It is possible that taking high doses of omega-3 fatty acid supplementations have positive effects on the heart and circulatory system and could protect from COVID-19 or decrease disease severity, in connection with a decrease in the ACE/ACE 2 ratio. On the other hand, omega-3 supplement may have negative effect on cardiovascular system due to the significant increase in serum LDL levels.
Keywords: 25- hydroxy vitamin D (25OHD); ACE; ACE/ACE2 ratio; ACE2; non-HDL; omega-3; vitamin D.
Copyright: © Pharmacy Practice.
Figures
Similar articles
-
Assessing the effect of omega-3 fatty acid combined with vitamin D3 versus vitamin D3 alone on estradiol levels: a randomized, placebo-controlled trial in females with vitamin D deficiency.Clin Pharmacol. 2019 Feb 4;11:25-37. doi: 10.2147/CPAA.S182927. eCollection 2019. Clin Pharmacol. 2019. PMID: 30787641 Free PMC article.
-
Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial.J Cardiovasc Pharmacol. 2023 Apr 1;81(4):251-258. doi: 10.1097/FJC.0000000000001398. J Cardiovasc Pharmacol. 2023. PMID: 36630694 Clinical Trial.
-
The effect of co supplementation of omega-3 and vitamin D on cardio metabolic risk factors and psychological distress in reproductive-aged women with prediabetes and hypovitaminosis D: a study protocol for a randomized controlled trial.Trials. 2019 Dec 30;20(1):799. doi: 10.1186/s13063-019-3948-5. Trials. 2019. PMID: 31888762 Free PMC article.
-
Nutritional interventions for treating foot ulcers in people with diabetes.Cochrane Database Syst Rev. 2020 Jul 17;7(7):CD011378. doi: 10.1002/14651858.CD011378.pub2. Cochrane Database Syst Rev. 2020. PMID: 32677037 Free PMC article.
-
Omega-3 fatty acid supplementation for cystic fibrosis.Cochrane Database Syst Rev. 2020 Apr 10;4(4):CD002201. doi: 10.1002/14651858.CD002201.pub6. Cochrane Database Syst Rev. 2020. PMID: 32275788 Free PMC article.
References
-
- 1. Mahmudpour M, Roozbeh J, Keshavarz M, et al. COVID-19 cytokine storm:The anger of inflammation. Cytokine. 2020;133(1):155151. https://doi.org/10.1016/j.cyto.2020.155151 - PMC - PubMed
- Mahmudpour M, Roozbeh J, Keshavarz M, et al. COVID-19 cytokine storm:The anger of inflammation. Cytokine. 2020;133(1):155151. doi: 10.1016/j.cyto.2020.155151. - DOI - PMC - PubMed
-
- 2. Chaudhary M. COVID-19 susceptibility:potential of ACE2 polymorphisms. Egyptian Journal of Medical Human Genetics. 2020;21(1):1-8. https://doi.org/10.1186/s43042-020-00099-9 - PMC - PubMed
- Chaudhary M. COVID-19 susceptibility:potential of ACE2 polymorphisms. Egyptian Journal of Medical Human Genetics. 2020;21(1):1–8. doi: 10.1186/s43042-020-00099-9. - DOI - PMC - PubMed
-
- 3. Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Translational Stroke Research. 2020;11(3):322-325. https://doi.org/10.1007/s12975-020-00818-9 - PMC - PubMed
- Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Translational Stroke Research. 2020;11(3):322–325. doi: 10.1007/s12975-020-00818-9. - DOI - PMC - PubMed
-
- 4. Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Current Cardiology Reports. 2020;22(5):31. https://doi.org/10.1007/s11886-020-01291-4 - PMC - PubMed
- Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Current Cardiology Reports. 2020;22(5):31. doi: 10.1007/s11886-020-01291-4. - DOI - PMC - PubMed
-
- 5. Bosso M, Thanaraj TA, Abu-Farha M, et al. The Two Faces of ACE2:The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Molecular therapy. Methods &Clinical Development. 2020;18(1):321-327. https://doi.org/10.1016/j.omtm.2020.06.017 - PMC - PubMed
- Bosso M, Thanaraj TA, Abu-Farha M, et al. The Two Faces of ACE2:The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Molecular therapy. Methods &Clinical Development. 2020;18(1):321–327. doi: 10.1016/j.omtm.2020.06.017. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous